Organon & Co. $OGN Shares Sold by Philip James Wealth Mangement LLC

Philip James Wealth Mangement LLC cut its position in shares of Organon & Co. (NYSE:OGN) by 0.8% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 877,837 shares of the company’s stock after selling 7,468 shares during the quarter. Organon & Co. comprises 1.1% of Philip James Wealth Mangement LLC’s portfolio, making the stock its 17th biggest position. Philip James Wealth Mangement LLC’s holdings in Organon & Co. were worth $8,497,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in OGN. Wellington Management Group LLP increased its stake in Organon & Co. by 44.2% during the fourth quarter. Wellington Management Group LLP now owns 32,966 shares of the company’s stock worth $492,000 after acquiring an additional 10,108 shares during the last quarter. GAMMA Investing LLC increased its stake in Organon & Co. by 4,172.4% during the first quarter. GAMMA Investing LLC now owns 68,658 shares of the company’s stock worth $1,022,000 after acquiring an additional 67,051 shares during the last quarter. NBC Securities Inc. increased its stake in Organon & Co. by 111,262.5% during the first quarter. NBC Securities Inc. now owns 8,909 shares of the company’s stock worth $132,000 after acquiring an additional 8,901 shares during the last quarter. Merit Financial Group LLC acquired a new stake in Organon & Co. during the first quarter worth about $205,000. Finally, RFG Advisory LLC acquired a new stake in Organon & Co. during the first quarter worth about $362,000. 77.43% of the stock is currently owned by institutional investors and hedge funds.

Organon & Co. Stock Performance

Shares of NYSE:OGN opened at $11.00 on Thursday. The firm has a market capitalization of $2.86 billion, a PE ratio of 4.09, a P/E/G ratio of 0.97 and a beta of 0.63. The company has a debt-to-equity ratio of 11.98, a current ratio of 1.65 and a quick ratio of 1.13. The business has a 50-day moving average of $9.82 and a two-hundred day moving average of $10.47. Organon & Co. has a 12 month low of $8.01 and a 12 month high of $19.05.

Organon & Co. (NYSE:OGN) last announced its quarterly earnings results on Tuesday, August 5th. The company reported $1.00 EPS for the quarter, topping the consensus estimate of $0.94 by $0.06. The company had revenue of $1.59 billion during the quarter, compared to analyst estimates of $1.55 billion. Organon & Co. had a return on equity of 163.88% and a net margin of 11.15%.The firm’s revenue was down .8% on a year-over-year basis. During the same period in the prior year, the firm posted $1.12 earnings per share. Organon & Co. has set its FY 2025 guidance at EPS. As a group, research analysts forecast that Organon & Co. will post 3.68 earnings per share for the current year.

Organon & Co. Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, September 11th. Stockholders of record on Friday, August 15th were paid a $0.02 dividend. The ex-dividend date was Friday, August 15th. This represents a $0.08 dividend on an annualized basis and a dividend yield of 0.7%. Organon & Co.’s dividend payout ratio (DPR) is 2.97%.

About Organon & Co.

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.